Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania
- Peter R Kisenge1,
- Alexander T Hawkins2,
- Venance P Maro1,
- John PD Mchele^3,
- Ndealilia S Swai3,
- Andreas Mueller1, 4 and
- Eric R Houpt2Email author
© Kisenge et al; licensee BioMed Central Ltd. 2007
Received: 06 October 2006
Accepted: 10 May 2007
Published: 10 May 2007
Largely due to the lack of diagnostic reagents, the prevalence and clinical presentation of cryptococcal meningitis in Tanzania is poorly understood. This in turn is limiting the impact of increased fluconazole availability.
We evaluated a cohort of 149 consecutive HIV-infected adult inpatients presenting with headache or altered mental status for clinical features, CD4 count, cryptococcal infection, and outcome. Cryptococcal meningitis was diagnosed via India ink and latex agglutination assay of CSF (n = 24 and 40 positive, respectively). Associations between cryptococcal meningitis and clinical features were evaluated by t-test. The sensitivity, specificity, and positive likelihood ratio of such features were determined.
Cryptococcal meningitis was associated with confusion, social withdrawal, seizures, fever, tachycardia, meningismus, oral candidiasis, and low Glasgow coma scales and CD4 count. CD4 count < 100/μl provided the highest sensitivity for the diagnosis (93%), coma (Glasgow coma scale ≤ 8) provided the highest specificity (84%), and the combination provided the highest positive likelihood ratio (3.8). All cryptococcal meningitis patients were initiated on 800 milligrams of fluconazole daily and 50% survived to discharge, however no clinical or laboratory findings correlated with prognosis.
Cryptococcal meningitis is common among Tanzanian HIV inpatients presenting with headache or altered mental status. Purely clinical features are insensitive for establishing the diagnosis or prognosis. We advocate expanding laboratory capacity for cryptococcal antigen testing to maximize survival.
Cryptococcus neoformans is a leading AIDS-associated opportunistic infection and a major cause of adult meningitis in studies from Central African Republic, South Africa, Zambia, Zimbabwe [1–4]. In one report cryptococcal meningitis (CM) was the first AIDS-defining illness in 88% of patients . The scope of the problem is less clear in Tanzania, where the literature is limited to one retrospective study that found Cryptococcus in 7% of (175/1144) CSF specimens . A major reason for this lack of clarity is the lack of diagnostic reagents. For instance the Medical Stores Department, the main distributor of medical reagents to Tanzania, does not procure either India ink or cryptococcal antigen tests . This leaves detection in the unlikely hands of expensive private imports. The need for accurate CM diagnosis is heightened by the increased availability of therapeutics to many parts of Africa, particularly fluconazole . We therefore chose to examine a large cohort of Tanzanian HIV inpatients with central nervous system presentations to determine the local rate of CM using CSF cryptococcal antigen testing as the gold standard. We also sought to determine whether particular clinical features could predict the diagnosis as a stopgap measure until diagnostic reagents for CM become more widely available.
Prevalence and clinical features of cryptococcal meningitis in Kilimanjaro region
Historical, examination, and laboratory findings in patients with cryptococcal meningitis.
Cryptococcal meningitis (n = 40)
Other (n = 109)
Age (median, range)
Subjective wt loss
On antiretroviral therapy
Febrile (T >38.0°C)
Hypertensive (>140/90 mm Hg)
Abnormal GCS (≤ 14)
Coma (GCS ≤ 8)
Leukocytes × 103/μl (median)
6.4 ± 7.1 (5.4)
6.1 ± 5.6 (6)*
Lymphocytes × 103/μl (median)
2.0 ± 1.3 (1.7)
1.9 ± 1.2 (2.0)
CD4 count/μl (median)
49.5 ± 45.2 (39)
190.0 ± 216.4 (89)
CD4 < 100/μl
Haemoglobin g/dl (median)
23.2 ± 29.1 (11.1)
17.9 ± 20.6 (12)*
Platelets × 103/μl (median)
161 ± 88 (141)
179 ± 104 (163)
87 ± 40 (93)
74 ± 39 (75)
Pleocytosis % > 2/μl (n)
63 ± 90
14 ± 23
53 ± 40
37 ± 34
47 ± 40
60 ± 34
CSF protein (g/L)†
1.2 ± 2.3
0.7 ± 0.7
CSF glucose (mmol/L)†
2.4 ± 1.3
3.0 ± 1.2
CSF opening pressure (mmHg)
14.2 ± 10.6
9.8 ± 8.6
Survival to discharge
Sensitivity and specificity of clinical features for the diagnosis
At the time of this study fluconazole was freely available, such that the physicians placed all patients with a positive CSF cryptococcal antigen test on 800 milligrams fluconazole per day orally or per nasogastric tube. Antiretroviral therapy (generally lamivudine, stavudine, and nevirapine) was either initiated or continued. Fifty percent (n = 20) of CM patients recovered and survived to discharge. CM was associated with mortality independent of CD4 count (18/37 CM patients with CD4 < 100/μl died vs. 15/56 non-CM patients with CD4 < 100/μl, P < 0.05). India ink positivity was not associated with a worse outcome (10/24 India ink positive patients died vs. 10/16 India ink negative CM patients; P = NS). Indeed, there was no statistical association between CM mortality and any of the clinical or laboratory indices measured (data not shown), only trends towards higher rates of hypertension (6/20 vs. 1/19; P = 0.09), higher opening pressure (median 14.5 vs. 10; P = 0.10), and higher erythrocyte sedimentation rates (median 106 vs. 78; P = 0.06) in the CM patients that died.
Our study shows that CM is common in northern Tanzania, occurring in 27% of HIV patients presenting with headache or AMS. The high rate is not surprising, although the magnitude of the problem had not been clear locally. Most reports on the severity of CM in Africa have originated from the South [1–3, 5], leading some to question whether the disease is less common in the East and West [13, 14]. Our results suggest the burden is also enormous in this region, similar to that seen in the Zimbabwe study .
The survival of our cohort was 50% to discharge. While less than the >80% survival seen in developed countries with the same 800 mg fluconazole regimen , our patients had far advanced disease and coma rates, and 50% survival is better than many reports from Africa [1, 16, 17]. Improved therapeutic regimens for CM are clearly needed, and one wonders if any added benefit would come from an additional agent such as flucytosine as seen in Uganda .
However we would advocate that improvements in therapeutics must be wed to improvements in diagnostics availability. During the time of study fluconazole was free (made available thanks to the Pfizer Diflucan Partnership Program), but this availability would have been aimless without cryptococcal antigen detection. Unfortunately, India ink exhibited a disappointing 60% sensitivity, worse than a clinical determination based on low CD4 count plus coma, therefore we are left advocating for increased availability of cryptococcal antigen tests (including use on serum ). As mentioned, the cryptococcal antigen test is presently not available through local dispensaries or Tanzania's Medical Stores Department, the country's main supplier of essential medicines and reagents. For the study tests were imported at a cost of $5.18 per test, admittedly not practical for a country whose per capita health expenditure is $12 . However even at this high price per test, assuming fluconazole costs the present $0.97 per 100 mg in Tanzania (and will not always be donated), the diagnostic vs. therapeutic cost per CM survivor remains miniscule.
The finding that low CD4 count plus coma was a reasonably sensitive and specific feature for CM is unfortunate. First, clearly it requires CD4 quantitation, which although is presently more available in our region of Tanzania, is also technically demanding and expensive. Secondly, the finding of coma may provide high specificity but will inherently miss earlier and better-prognosis presentations . Therefore while intuitively appealing to devise clinical management algorithms in settings with limited laboratory resources, we by no means advocate clinical diagnosis for this entity and would simply emphasize that the knowledge of CD4 < 100/μl plus coma in Tanzania should prompt strong consideration of CM.
Given CM's high mortality in Africa it seems prudent to examine preventive approaches instead of waiting until patients have advanced disease. We would predict that fluconazole prophylaxis in Tanzanian patients with CD4 < 100/μl, although costly, would prevent mortality (in contrast to the American study ). Alternatively, periodic screening of such patients with serum cryptococcal antigen could be comparator approach, accepting that this switches cost and infrastructure demands to the laboratory instead of the pharmacy.
There were a few final observations from our study. First, all patients underwent lumbar puncture, and this showed that many HIV patients with headache or altered mental status do not have meningitis. In many resource-limited settings where lumbar puncture is not performed due to erratic availability of equipment, empiric antibiotics are the norm, and our data would suggest this is often unnecessary and a waste of resources. Additionally, of the 149 admissions we document, 21% (24/113) of patients with CD4 < 200/μl were already on antiretroviral therapy, a starting point towards WHO and Global Fund goals.
Cryptococcal meningitis is common among Tanzanian HIV inpatients presenting with headache or altered mental status. Given the insensitivity of purely clinical features for establishing the diagnosis or prognosis, we advocate expanding laboratory capacity for cryptococcal antigen testing to maximize survival.
Patients aged 13 – 65 were enrolled from the inpatient medical ward of the Kilimanjaro Christian Medical Centre (KCMC) from June 2005 – May 2006. Eligible patients included 162 consecutive HIV-positive inpatients with headache and/or altered mental status (Glasgow coma scale < 14). Thirteen patients were excluded from evaluation by lumbar puncture for concerns of papilloedema (3), cranial nerve palsies (2), or focal motor deficits (8). Informed consent for lumbar puncture was obtained from all participants, the University of Virginia Human Investigation Committee and the Kilimanjaro Christian Medical Centre Ethics Committee reviewed and approved the project, and all research was in compliance with the Helsinki Declaration. Patient histories came from the patient when possible else the patient's friends and/or family. All therapies were ordered by the consultant physician. Chart review demonstrated that all CM patients were initiated on 800 mg fluconazole (Diflucan, Pfizer, New York, NY) orally or per nasogastric tube for 2 weeks, followed by 400 mg orally for 4 weeks, followed by 200 mg orally thereafter. Of note, amphotericin B and flucytosine were not available in Tanzania at the time of this study, nor are they presently.
Cryptococcal infection was assayed in cerebrospinal fluid by India ink testing (Becton Dickinson, Sparks, MD) and cryptococcal antigen latex agglutination (Murex Cryptococcus Test, Remel, Lenexa, KS). CD4 count was measured using the Coulter Manual CD4 Count kit (Beckman Coulter, Hialeah, FL). Haematology assays on CSF were performed at the KCMC Clinical laboratory with a Coulter counter and by microscopy.
Statistics and diagnostic performance
Means and medians were compared using t test and Mann-Whitney test, respectively. All P values are two-tailed. Data shown are mean ± SD unless otherwise indicated. In accordance with STARD guidelines, the CSF cryptococcal antigen assay was utilized as the gold-standard test for the diagnosis of CM. Confidence intervals for proportions (sensitivity and specificity) were calculated using the Wilson score method . Confidence intervals for positive and negative likelihood ratios were calculated as previously described . The Youden's J index is used to rate the overall performance of a test and is calculated by (sensitivity + specificity - 1), where 0 is worthless and 1 is perfect. The positive likelihood ratio (= true positive rate/false positive rate) has been shown to be a superior method to convey the diagnostic value of a positive test result to clinicians .
Kilimanjaro Christian Medical Centre
We thank W. Michael Scheld for support and reviewing the manuscript and the KCMC-Duke collaboration on HIV/AIDS for facilitating provision of fluconazole from Axios International. We are grateful for the Pfizer Diflucan Partnership Program, which allowed 20 survivors, many of whom remain completely well. This manuscript is dedicated to the memory of John P.D. Mchele. This work was supported by the University of Virginia Center for Global Health Pfizer initiative (A.H. is a Pfizer-CGH scholar). This funding body played no role in study design, analysis, or reporting. The authors have no financial or non-financial competing interests.
This work was supported by the University of Virginia Center for Global Health Pfizer initiative (A.H. is a Pfizer-CGH scholar).
- Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A: Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J. 2001, 77: 769-773. 10.1136/pmj.77.914.769.View ArticlePubMedPubMed CentralGoogle Scholar
- Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, Robertson VJ, Musvaire P, Mason PR: Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. Aids. 2000, 14: 1401-1407. 10.1097/00002030-200007070-00013.View ArticlePubMedGoogle Scholar
- Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, Grant AD, Murray J, Hayes RJ, De Cock KM: Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis. 2002, 34: 1251-1258. 10.1086/339540.View ArticlePubMedGoogle Scholar
- Bekondi C, Bernede C, Passone N, Minssart P, Kamalo C, Mbolidi D, Germani Y: Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis. 2006, 10: 387-395. 10.1016/j.ijid.2005.07.004.View ArticlePubMedGoogle Scholar
- Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, Robertson VJ, Mason PR: Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis. 1998, 26: 284-289.View ArticlePubMedGoogle Scholar
- Matee MI, Matre R: Pathogenic isolates in meningitis patients in Dar Es Salaam, Tanzania. East Afr Med J. 2001, 78: 458-460.View ArticlePubMedGoogle Scholar
- Price Catalogue of Essential Medicines and Hospital Supplies. 2007, Dar es Salaam, Tanzania
- Sebati K: Pfizer Diflucan Partnership Program. Lancet. 2003, 361: 72; author reply 72-10.1016/S0140-6736(03)12124-1.View ArticlePubMedGoogle Scholar
- Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004, 363: 1764-1767. 10.1016/S0140-6736(04)16301-0.View ArticlePubMedGoogle Scholar
- Okongo M, Morgan D, Mayanja B, Ross A, Whitworth J: Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol. 1998, 27: 698-702. 10.1093/ije/27.4.698.View ArticlePubMedGoogle Scholar
- Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R: Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999, 353: 1463-1468. 10.1016/S0140-6736(98)07399-1.View ArticlePubMedGoogle Scholar
- Menichetti F, Fiorio M, Tosti A, Gatti G, Bruna Pasticci M, Miletich F, Marroni M, Bassetti D, Pauluzzi S: High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996, 22: 838-840.View ArticlePubMedGoogle Scholar
- Maher D, Mwandumba H: Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. J Infect. 1994, 28: 59-64. 10.1016/S0163-4453(94)94161-0.View ArticlePubMedGoogle Scholar
- French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, Lalloo D, Whitworth JA, Gilks CF: Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002, 16: 1031-1038. 10.1097/00002030-200205030-00009.View ArticlePubMedGoogle Scholar
- Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, Izumi T, Ococi J, Augustine K, Mugerwa R, Nagatake T, Matsumoto K: Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis. 1998, 26: 1362-1366.View ArticlePubMedGoogle Scholar
- Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A: Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis. 1996, 23: 827-830.View ArticlePubMedGoogle Scholar
- World Health Report. 2006, Geneva, World Health Organization
- Diamond RD, Bennett JE: Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974, 80: 176-181.View ArticlePubMedGoogle Scholar
- Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, Koletar SL, Eyster ME, Carey J, Waskin H, et al: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995, 332: 700-705. 10.1056/NEJM199503163321102.View ArticlePubMedGoogle Scholar
- Newcombe RG: Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998, 17: 873-890. 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
- Simel DL, Samsa GP, Matchar DB: Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991, 44: 763-770. 10.1016/0895-4356(91)90128-V.View ArticlePubMedGoogle Scholar
- Steurer J, Fischer JE, Bachmann LM, Koller M, ter Riet G: Communicating accuracy of tests to general practitioners: a controlled study. Bmj. 2002, 324: 824-826. 10.1136/bmj.324.7341.824.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/7/39/prepub